Parietal cell density during gastric ulcer healing in the rat.
BACKGROUND
During the healing of gastric ulcers, extensive changes take place in the structure and proportion of the parietal cells in the ulcer margin. We aimed to determine whether these changes are influenced by compounds or by procedures that may promote or delay gastric ulcer healing.


METHODS
Acetic acid ulcers were produced in the rat gastric corpus; control rats were non-operated or sham-operated. All rats were provided with an osmotic minipump releasing 3H-thymidine for determination of the labelling index (LI). The rats were given omeprazole, gastrin or indomethacin, infected with Helicobacter pylori, or subjected to anterior vagotomy. They were killed after 1, 2, 6 or 13 days, and the ulcer margin and undamaged corpus wall were excised for histology. The proportion of parietal cells was calculated in relation to the total number, and the total volume, of the epithelial cells.


RESULTS
The parietal cells averaged 16%-21% of the number and 30%-32% of the volume of the epithelial cells in the unoperated control rats, but considerably less in the ulcer margin. This reduction was partially prevented by indomethacin. In the undamaged, dorsal epithelium the parietal cells increased to 23%-26% of the number, and 41%-47% of the volume, of the epithelial cells, both in the ulcer rats and in the sham-operated rats. The LI of the parietal cells was 6% in the undamaged epithelium of the 13-day ulcer rats, but close to 0% in all other groups examined.


CONCLUSIONS
Indomethacin prevents much of the loss of parietal cells in the ulcer margin. In the undamaged epithelium of the ulcer rats there is an increased proportion of parietal cells. The new parietal cells are not formed directly from dividing cells, but are probably recruited from existing precursor cells.
Dept of GastroResearch, University of Göteborg, Sweden. herberthelander@hotmail.com
H F
HF
Helander
N
N
Poorkhalkali
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002452:Cell Count; D005260:Female; D016481:Helicobacter Infections / Q000150:complications; D007213:Indomethacin / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010295:Parietal Cells, Gastric / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013276:Stomach Ulcer / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D013936:Thymidine / Q000031:analogs & derivatives* / Q000502:physiology; D014945:Wound Healing / Q000502:physiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; C012439:methylthymidine; D009853:Omeprazole; D013936:Thymidine; D007213:Indomethacin